CTI BioPharma (CTIC)

Company Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.

Company profile

Ticker

CTIC

Exchange

NASDAQ

Website

www.ctibiopharma.com

CEO

Adam Craig

Incorporated

Delaware

Location

Washington

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

CELL THERAPEUTICS INC

SEC CIK

0000891293

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

911533912

CTIC stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6 Mar 23

CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

7 Nov 22

CTI BioPharma Reports Third Quarter 2022 Financial Results

7 Nov 22

8-K

Departure of Directors or Certain Officers

Notice of effectiveness

26 Aug 22

CORRESP

Correspondence with SEC

Transcripts

View all

CTIC

Earnings call transcript

2022 Q4

6 Mar 23

CTIC

Earnings call transcript

2022 Q3

8 Nov 22

CTIC

Earnings call transcript

2022 Q2

9 Aug 22

CTIC

Earnings call transcript

2022 Q1

12 May 22

CTIC

Earnings call transcript

2021 Q2

6 Aug 21

CTIC

Earnings call transcript

2021 Q1

2 Jun 21

CTIC

Earnings call transcript

2020 Q4

17 Mar 21

CTIC

Earnings call transcript

2020 Q3

10 Nov 20

CTIC

Earnings call transcript

2018 Q3

1 Nov 18

CTIC

Earnings call transcript

2018 Q2

2 Aug 18

Latest ownership filings

View all

Stonepine Capital Management, LLC

MILLENNIUM MANAGEMENT LLC

9 Jan 23

Financial summary

Financial statements Chart CTIC financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	30.42 mm	30.42 mm	30.42 mm	30.42 mm	30.42 mm	30.42 mm
Cash burn (monthly)	542.67 k	2.92 mm	4.53 mm	6.65 mm	5.17 mm	6.77 mm
Cash used (since last report)	1.51 mm	8.12 mm	12.61 mm	18.50 mm	14.38 mm	18.82 mm
Cash remaining	28.91 mm	22.30 mm	17.81 mm	11.92 mm	16.04 mm	11.60 mm
Runway (months of cash)	53.3	7.6	3.9	1.8	3.1	1.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

CTIC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	146	134	+9.0%
Opened positions	38	27	+40.7%
Closed positions	26	16	+62.5%
Increased positions	47	48	-2.1%
Reduced positions	37	44	-15.9%

13F shares	Current	Prev Q	Change
Total value	617.14 bn	703.12 mm	+87671.8%
Total shares	143.09 mm	122.00 mm	+17.3%
Total puts	63.00 k	637.60 k	-90.1%
Total calls	2.02 mm	676.10 k	+198.5%
Total put/call ratio	0.0	0.9	-96.7%

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	28.46 mm	$177.33 mm	0.0%
STT State Street	16.00 mm	$96.18 bn	NEW
Growth Equity Opportunities V	9.61 mm	$51.24 mm	0.0%
BVF	8.81 mm	$52.97 bn	0.0%
BLK Blackrock	7.06 mm	$42.43 bn	+7.0%
Vanguard	5.57 mm	$33.48 bn	+16.4%
Stonepine Capital Management	4.93 mm	$29.65 bn	-13.0%
Millennium Management	4.76 mm	$28.55 bn	+0.2%
Sofinnova Investments	4.61 mm	$27.69 bn	+27.5%
Bleichroeder	3.89 mm	$23.40 bn	-1.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	16.00 mm	+16.00 mm	NEW
Bain Capital Life Sciences Investors	3.78 mm	+3.78 mm	NEW
Point72 Asset Management	1.76 mm	+1.65 mm	+1529.0%
Driehaus Capital Management	0.00	-1.63 mm	EXIT
Voloridge Investment Management	0.00	-1.58 mm	EXIT
AIGH Capital Management	1.41 mm	+1.41 mm	NEW
Sofinnova Investments	4.61 mm	+994.15 k	+27.5%
Balyasny Asset Management	871.41 k	+871.41 k	NEW
Vanguard	5.57 mm	+785.39 k	+16.4%
UBS UBS Group AG - Registered Shares	926.31 k	+782.05 k	+542.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CTIC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Mar 23	James K Fong	Stock Option Common Stock	Grant	Acquire A	No	No	4.55	200,000	910.00 k	200,000
14 Mar 23	Adam R Craig	Stock Option Common Stock	Grant	Acquire A	No	No	4.55	900,000	4.10 mm	900,000
14 Mar 23	David Kirske	Stock Option Common Stock	Grant	Acquire A	No	No	4.55	200,000	910.00 k	200,000
24 Jan 23	James K Fong	common stock	Sell	Dispose S	No	Yes	6	100,000	600.00 k	3,565
24 Jan 23	James K Fong	common stock	Option exercise	Acquire M	No	No	0.9489	100,000	94.89 k	103,565
24 Jan 23	James K Fong	NQSO Common Stock	Option exercise	Dispose M	No	No	0.9489	100,000	94.89 k	188,000
24 Jan 23	Adam R Craig	common stock	Sell	Dispose S	No	Yes	6.01	2,117	12.72 k	29,440
24 Jan 23	Adam R Craig	common stock	Option exercise	Acquire M	No	No	0.8411	2,117	1.78 k	31,557
24 Jan 23	Adam R Craig	common stock	Sell	Dispose S	No	Yes	6	83,200	499.20 k	29,440
24 Jan 23	Adam R Craig	common stock	Option exercise	Acquire M	No	No	0.8411	83,200	69.98 k	112,640